Comparing Oramed Pharmaceuticals (NASDAQ:ORMP) & Allakos (NASDAQ:ALLK)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Earnings and Valuation

This table compares Oramed Pharmaceuticals and Allakos”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$1.34 million	72.41	$5.53 million	$0.51	4.67
Allakos	N/A	N/A	-$185.70 million	($2.34)	-0.28

Oramed Pharmaceuticals has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Insider and Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 16.1% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Oramed Pharmaceuticals and Allakos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	2.70%	2.10%
Allakos	N/A	-123.58%	-82.95%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oramed Pharmaceuticals and Allakos, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Allakos	1	2	2	0	2.20

Allakos has a consensus target price of $1.67, suggesting a potential upside of 155.82%. Given Allakos’ stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Oramed Pharmaceuticals.

Summary

Oramed Pharmaceuticals beats Allakos on 7 of the 12 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Allakos

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.